Prothena Beheer

Beheer criteriumcontroles 2/4

De CEO Prothena is Gene Kinney, benoemd in Sep2016, heeft een ambtstermijn van 8.17 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 7.04M, bestaande uit 9% salaris en 91% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.024% van de aandelen van het bedrijf, ter waarde $ 192.88K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 7.7 jaar en 5.1 jaar.

Belangrijke informatie

Gene Kinney

Algemeen directeur

US$7.0m

Totale compensatie

Percentage CEO-salaris	9.0%
Dienstverband CEO	8.2yrs
Eigendom CEO	0.02%
Management gemiddelde ambtstermijn	7.7yrs
Gemiddelde ambtstermijn bestuur	5.1yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Gene Kinney's beloning veranderd ten opzichte van Prothena's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$132m
Jun 30 2024	n/a	n/a	-US$51m
Mar 31 2024	n/a	n/a	-US$172m
Dec 31 2023	US$7m	US$631k	-US$147m
Sep 30 2023	n/a	n/a	-US$73m
Jun 30 2023	n/a	n/a	-US$141m
Mar 31 2023	n/a	n/a	-US$128m
Dec 31 2022	US$7m	US$601k	-US$117m
Sep 30 2022	n/a	n/a	-US$156m
Jun 30 2022	n/a	n/a	-US$1m
Mar 31 2022	n/a	n/a	US$67m
Dec 31 2021	US$5m	US$573k	US$67m
Sep 30 2021	n/a	n/a	US$69m
Jun 30 2021	n/a	n/a	-US$70m
Mar 31 2021	n/a	n/a	-US$124m
Dec 31 2020	US$3m	US$554k	-US$111m
Sep 30 2020	n/a	n/a	-US$102m
Jun 30 2020	n/a	n/a	-US$91m
Mar 31 2020	n/a	n/a	-US$80m
Dec 31 2019	US$3m	US$538k	-US$78m
Sep 30 2019	n/a	n/a	-US$79m
Jun 30 2019	n/a	n/a	-US$84m
Mar 31 2019	n/a	n/a	-US$128m
Dec 31 2018	US$11m	US$525k	-US$156m
Sep 30 2018	n/a	n/a	-US$181m
Jun 30 2018	n/a	n/a	-US$209m
Mar 31 2018	n/a	n/a	-US$167m
Dec 31 2017	US$5m	US$521k	-US$153m

Compensatie versus markt: De totale vergoeding ($USD 7.04M ) Gene } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de UK markt ($USD 1.45M ).

Compensatie versus inkomsten: De vergoeding van Gene is gestegen terwijl het bedrijf verliesgevend is.

CEO

Gene Kinney (55 yo)

8.2yrs

Tenure

US$7,043,826

Compensatie

Dr. Gene G. Kinney, Ph D., has been the Chief Executive Officer and President of Prothena Corporation plc since September 26, 2016 and October 3, 2016 respectively and served as its Chief Operating Officer...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Gene Kinney	President	8.2yrs	US$7.04m	0.024% $ 192.9k
Tran Nguyen	CFO & Chief Strategy Officer	11.7yrs	US$2.70m	0.0060% $ 48.3k
Brandon Smith	Chief Operating Officer	3.1yrs	US$2.63m	0% $ 0
Carol Karp	Chief Regulatory Officer	7.9yrs	US$2.57m	0% $ 0
Karin Walker	Chief Accounting Officer & Controller	11.5yrs	geen gegevens	geen gegevens
Wagner Zago	Chief Scientific Officer	7.4yrs	US$3.34m	geen gegevens
Mark Johnson	Vice President of Investor Relations	no data	geen gegevens	geen gegevens
Michael Malecek	Chief Legal Officer	no data	US$1.18m	geen gegevens
David Ford	Chief People Officer	less than a year	geen gegevens	geen gegevens
Chad Swanson	Chief Development Officer	less than a year	geen gegevens	geen gegevens
Yvonne Tchrakian	Company Secretary	no data	geen gegevens	geen gegevens

7.7yrs

Gemiddelde duur

55yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 0Y3M is doorgewinterd en ervaren (gemiddelde ambtstermijn van 7.7 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Gene Kinney	President	8.2yrs	US$7.04m	0.024% $ 192.9k
Helen Kim	Independent Director	2.3yrs	US$896.63k	0% $ 0
Richard Collier	Independent Director	11.9yrs	US$912.48k	0.0023% $ 18.4k
Daniel Welch	Independent Chairman	less than a year	geen gegevens	geen gegevens
Lars Ekman	Independent Chair Emeritus	less than a year	US$923.48k	0.00045% $ 3.7k
Shane Cooke	Independent Director	11.9yrs	US$917.26k	0% $ 0
Dennis Selkoe	Independent Director	11.3yrs	US$901.73k	0.0078% $ 63.5k
Paula Cobb	Independent Director	5.3yrs	US$908.48k	0% $ 0
Oleg Nodelman	Independent Director	4.9yrs	geen gegevens	geen gegevens
William Dunn	Independent Director	1.5yrs	US$1.70m	geen gegevens

5.1yrs

Gemiddelde duur

62yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 0Y3M wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.1 jaar).

Prothena Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Prothena Corporation plc Announces Appointment of Chad Swanson as Chief Development Officer

Prothena Corporation plc, Annual General Meeting, May 14, 2024

Prothena Appoints David Ford to Newly Created Chief People Officer

Prothena Corporation plc Announces Board Changes

Prothena Corporation plc Appoints Billy Dunn to its Board of Directors

Prothena Corporation plc Appoints Helen S. Kim to its Board of Directors

Recent updates

Third quarter 2024 earnings released: US$1.10 loss per share (vs US$0.41 profit in 3Q 2023)

Prothena Corporation plc to Report Q3, 2024 Results on Nov 12, 2024

Prothena Corporation plc Announces Appointment of Chad Swanson as Chief Development Officer

Second quarter 2024 earnings released: EPS: US$1.24 (vs US$1.03 loss in 2Q 2023)

Prothena Corporation plc Revises Financial Guidance for the Full Year of 2024

Prothena Corporation plc to Report Q2, 2024 Results on Aug 08, 2024

First quarter 2024 earnings released: US$1.35 loss per share (vs US$0.89 loss in 1Q 2023)

Prothena Corporation plc to Report Q1, 2024 Results on May 08, 2024

Prothena Corporation plc, Annual General Meeting, May 14, 2024

Prothena Appoints David Ford to Newly Created Chief People Officer

Full year 2023 earnings released: US$2.76 loss per share (vs US$2.47 loss in FY 2022)

Prothena Corporation plc has filed a Follow-on Equity Offering in the amount of $250 million.

Prothena Corporation plc Announces Board Changes

Full year 2023 earnings released: US$2.76 loss per share (vs US$2.47 loss in FY 2022)

Prothena Corporation plc Provides Earnings Guidance for the Year 2024

Prothena Corporation plc to Report Q4, 2023 Results on Feb 15, 2024

New major risk - Revenue and earnings growth

Third quarter 2023 earnings released: EPS: US$0.41 (vs US$0.97 loss in 3Q 2022)

Prothena Corporation plc to Report Q3, 2023 Results on Nov 02, 2023

Prothena Reportedly Prepares for Potential Sale

Prothena Reportedly Prepares for Potential Sale

Second quarter 2023 earnings released: US$1.03 loss per share (vs US$0.88 loss in 2Q 2022)

Prothena Corporation plc to Report Q2, 2023 Results on Aug 03, 2023

Prothena Corporation plc Presents New Research in the Treatment of Alzheimer's Disease At Alzheimer's Association International Conference®? 2023

Prothena C Corporation plc Announces Phase VITAL Clinical Trial Results Published in Blood Showing Survival Benefit in Patients with Mayo Stage IV Al Amyloidosis Treated with Birtamimab

Prothena Corporation plc Appoints Billy Dunn to its Board of Directors

First quarter 2023 earnings released: US$0.89 loss per share (vs US$0.78 loss in 1Q 2022)

Prothena Corporation plc Provides Earnings Guidance for the Year 2023

Full year 2022 earnings released: US$2.47 loss per share (vs US$1.51 profit in FY 2021)

Prothena Corporation plc to Report Q4, 2022 Results on Feb 23, 2023

Prothena Corporation plc Reports Topline Phase 1 Single Ascending Dose Study Results of PRX005

Prothena Corporation plc Presents Data Demonstrating Consistent Survival Benefit Observed with Birtamimab in Mayo Stage IV AL Amyloidosis Patients in Phase 3 VITAL Study at ASH 2022

Third quarter 2022 earnings released: US$0.97 loss per share (vs US$2.39 profit in 3Q 2021)

Prothena Corporation plc to Report Q3, 2022 Results on Nov 03, 2022

Prothena Corporation plc Appoints Helen S. Kim to its Board of Directors

Second quarter 2022 earnings released: US$0.88 loss per share (vs US$0.62 profit in 2Q 2021)

Prothena Corporation plc Provides Earnings Guidance for the Year 2022

Prothena Corporation plc to Report Q2, 2022 Results on Aug 08, 2022

Prothena Corporation plc(NasdaqGS:PRTA) dropped from Russell Microcap Value Index

Investor sentiment deteriorated over the past week

Prothena Corporation plc Receives FDA Fast Track Designation for PRX012, a Next-Generation Anti-Amyloid Beta Antibody Under Investigation for the Treatment of Alzheimer's Disease

Prothena Corporation plc, Annual General Meeting, May 17, 2022

Prothena Corporation plc Announces U.S. Food and Drug Administration Clearance of IND for PRX012, A Subcutaneous Anti-Amyloid Beta Antibody Under Investigation for the Treatment of Alzheimer’s Disease

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Prothena Corporation plc Provides Earnings Guidance for the Year 2022

Prothena Corporation plc to Report Q4, 2021 Results on Feb 17, 2022

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Third quarter 2021 earnings released: EPS US$2.39 (vs US$0.77 loss in 3Q 2020)

Forecast to breakeven in 2021

Second quarter 2021 earnings released: EPS US$0.62 (vs US$0.66 loss in 2Q 2020)

Forecast to breakeven in 2021

Forecast to breakeven in 2021

First quarter 2021 earnings released: US$0.91 loss per share (vs US$0.59 loss in 1Q 2020)

Prothena Corporation plc Provides Earnings Guidance for the Year 2021

Revenue beats expectations

Full year 2020 earnings released: US$2.79 loss per share (vs US$1.95 loss in FY 2019)

Prothena Corporation plc Announces Promising New Preclinical and Clinical Data from Its Neurodegenerative Programs Selected for Oral Presentations At AD/PD 2021

Full year 2020 earnings released: US$2.79 loss per share (vs US$1.95 loss in FY 2019)

Revenue beats expectations

Prothena Corporation plc to Report Q4, 2020 Results on Feb 11, 2021

Prothena Corporation plc Announces Confirmatory Phase 3 AFFIRM-AL Study of Birtamimab in Mayo Stage IV Patients with AL Amyloidosis under SPA Agreement with FDA

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd